SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to a sharp after-hours surge, fueled by a strong fiscal year revenue report showing significant year-over-year growth. The community is actively discussing its low float and potential for a substantial move, with some anticipating a short squeeze. Traders are watching for volume confirmation to validate further upside potential.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending as community members discuss its potential as an undervalued Bitcoin and AI data center play. Investors are reacting to news of HIVE's expansion in Paraguay, targeting increased Bitcoin mining power and a fivefold growth in AI operations. Bullish sentiment is fueled by rising Bitcoin prices and optimism surrounding the company's transition into high-performance computing.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community discusses potential catalysts stemming from activity surrounding the White House's social media, drawing comparisons to the stock's previous surges. Community members are debating the potential impact of this activity and its implications for a possible short squeeze. The stock's movement is also being compared to other meme stocks like BYND, with some suggesting a rotation of interest.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as traders discuss recent price action and potential catalysts, with community members debating the stock's valuation and future performance. Active discussions involve the impact of potential acquisitions, analysis of short interest, and the company's growth strategy in the hereditary angioedema (HAE) market. Community members are weighing the company's pipeline and revenue prospects against current market conditions.

ETHZilla Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palm Beach, FL.

ETHZilla Corp

ETHZilla Corporation

ETHZilla is trending as community members discuss its relationship to the price of Ethereum and potential for a short squeeze, with some drawing comparisons to other meme stocks. Despite positive movement in ETH, ETHZ is struggling to follow, leading to frustration and questions around dilution and management strategy. Discussions also include the upcoming reverse stock split and its potential impact on institutional investment.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amid speculation of a potential acquisition of Warner Bros. Discovery, with discussions around deal structures and valuations driving community interest.  Community members are debating the potential impact of the merger, with some focused on the involvement of key figures like Taylor Sheridan and the integration of UFC content, while others analyze potential price targets. The stock's movement is further fueled by discussions around cost-cutting plans, potential subscriber growth, and the broader media landscape.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending amid rumors of a potential acquisition by Novartis ($NVS), sending the stock soaring. The community speculates on the deal's likelihood and potential value, while noting positive clinical data and a strengthened pipeline. Discussions also involve the impact on the broader RNA therapeutics sector and comparisons to other companies in the space.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

OPEN is trending as the community discusses potential catalysts including real estate tokenization, a possible partnership with Robinhood, and upcoming earnings. Bullish investors are pointing to technical indicators and a new CEO, while bears cite concerns about cash flow and dilution. Some traders are drawing comparisons to other meme stocks, speculating on possible short squeezes and volatile price swings.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending as investors discuss the potential acquisition of Larvotto Resources and its impact on the company's standing in the antimony market. Community members are weighing the pros and cons of the deal, especially in light of geopolitical factors and UAMY's existing position as a domestic supplier. Chatter revolves around the company's potential for growth and the possibility of government involvement.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is trending as the community speculates on potential upside, fueled by news of 'Bitcoin Jesus' resolving tax charges and broader discussions around altcoin season. Chatter revolves around BCH potentially outperforming Bitcoin, along with anticipation of a spot ETF and its inclusion in retirement accounts. Community members are pointing to technical indicators, such as breaking out of a symmetrical triangle, as reasons for optimism.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

Equity

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.


CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.

U.S. equities declined in Wednesday’s afternoon trade as investors cautiously await the release of key economic data this week, including the third estimate of gross domestic product (GDP) for the second quarter (Q2) on Thursday, and the personal consumption expenditures (PCE) price index on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.39% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.6%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.31%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lithium-americas-stock-surge-captures-wall-street-attention-here-is-why/chD1GtUR33g">confirmed</a> that it is in talks with the U.S. Department of Energy and its joint venture partner General Motors Co. (GM) in the Thacker Pass lithium project over the renegotiation of a $2.26 billion Energy Department loan.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 101% year-to-date.<a href="https://stocktwits.com/symbol/BABA">Alibaba Group Holdings (BABA)</a>Alibaba’s U.S.-listed shares surged more than 9% in Wednesday’s afternoon session after the company announced plans to boost investment in artificial intelligence by over $53 billion.<a href="https://stocktwits.com/symbol/BABA">BABA stock</a> is up 110% year-to-date.<a href="https://stocktwits.com/symbol/QURE">uniQure NV (QURE)</a>uniQure shares soared more than 260% on Wednesday afternoon after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">said</a> that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 178% year-to-date.<a href="https://stocktwits.com/symbol/IREN">IREN (IREN)</a>IREN shares surged over 16% on Wednesday afternoon following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-surged-15-percent-today-here-is-a-price-target-update/chD1drjR33t">announcement</a> by the company that it has doubled its AI Cloud capacity to a total of 23,000 GPUs (graphic processing units), supporting the company’s goal of achieving more than $500 million in annualized AI Cloud revenue by the first quarter of 2026.<a href="https://stocktwits.com/symbol/IREN">IREN stock</a> is up 393% year-to-date.<a href="https://stocktwits.com/symbol/CDTX">Cidara Therapeutics Inc. (CDTX)</a>Cidara shares gained over 21% in Wednesday’s afternoon trade after the company announced plans for a Phase 3 study for CD388, a non-vaccine preventative of seasonal influenza.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up 232% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-surprised-by-strength-of-fed-chair-candidates/chD1cDJR33N">Scott Bessent Says He’s Surprised By Strength Of Fed Chair Candidates: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Shares of Cidada Therapeutics doubled in value on Monday&nbsp;and jumped in after-hours trading as the biotech firm released positive results from a trial of its flu drug candidate,&nbsp;managing to offset pressure from plans for a $250 million share offering.Cidara will offer all shares, and underwriters will receive a 30-day option to buy up to 15% more shares.&nbsp;J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor are leading the deal.&nbsp;The disclosure&nbsp;follows a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cidara-therapeutics-market-cap-doubles-after-investigational-drug-shows-positive-results-in-preventing-influenza/chm5alCRRdd">mid-stage trial of CD388</a>, a long-acting antiviral being developed to protect against seasonal flu.&nbsp;In the trial, which enrolled healthy adults between 18 and 64 who had not been given flu vaccines, CD388 was administered in three single doses.Each dose showed statistically meaningful protection against the flu over a 24-week period, with the highest dose offering up to 76% protection.Cidara said the treatment was well tolerated at all tested levels, with no significant safety concerns.Based on the outcome, the company has formally asked the U.S. Food and Drug Administration (USFDA) to hold a meeting to review the findings and discuss next steps for a Phase 3 trial.CD388 is being developed using Cidara’s Cloudbreak platform and is designed to offer once-per-season protection against both influenza A and B viruses.&nbsp;The company expects to share further results at upcoming medical meetings.Following the update, H.C. Wainwright raised its price target on Cidara Therapeutics to $53 from $41, citing strong mid-stage trial results for CD388 and boosting its success probability to 75%.&nbsp;RBC Capital also lifted its target to $75 from $35, calling CD388 a potentially groundbreaking long-acting flu preventative.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 31,400% surge in 24-hour message volume.One user said Cidara’s rally was unusual for a company announcing a large capital raise, warning short sellers to be cautious.&nbsp;<stembedurl>https://stocktwits.com/Stmkr/message/618765398</stembedurl>Another user noted that no price had been set for the offering yet and said they planned to watch how the situation unfolds in the next session.<stembedurl>https://stocktwits.com/Lstreak/message/618734296</stembedurl>The stock has risen 64.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering

The offering is being led by J.P. Morgan, Morgan Stanley, Guggenheim Securities, and Cantor.

Cidara Therapeutics, Inc. (CDTX) on Monday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cidara.com/news/cidara-therapeutics-announces-positive-topline-results-from-its-phase-2b-navigate-trial-evaluating-cd388-a-non-vaccine-preventative-of-seasonal-influenza/">announced</a> positive results from its mid-stage trial evaluating CD388 for the prevention of seasonal influenza in healthy unvaccinated adults aged 18 to 64.Cidara’s shares nearly doubled in value as of Monday afternoon.Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said. The doses were administered at the beginning of the flu season.CD388 was well-tolerated at all doses with no unexpected dose-limiting treatment-emergent adverse events observed, the company added.CD388 is not a vaccine. Instead, it is an investigational drug-Fc conjugate (DFC), or low molecular weight biologics, which are designed to function as long-acting small molecule inhibitors.As it is not a vaccine, its activity is not reliant on an immune response and, thereby, is expected to be efficacious in individuals regardless of immune status.CEO Jeffrey Stein stated that the trial results reinforce the company’s confidence in the potential of CD388 to provide seasonal protection against influenza A and B.Cidara stated that it has submitted a request to the U.S. Food and Drug Administration to review the results of the mid-stage trial and discuss the design and timing of a late-stage trial.Following the update, H.C. Wainwright raised its price target on Cidara to $53 from $41 and kept a ‘Buy’ rating on the shares.The new price target implies a 152% upside to the stock’s closing price on Friday.The analyst further increased the probability of success for CD388 to 75% from 60% based on the positive mid-stage trial data.RBC Capital also raised the firm's price target on Cidara Therapeutics to $75 from $35 while keeping an 'Outperform' rating on the shares. The results from the recent study position CD388 as a potential groundbreaking, long-acting flu preventative that could combine and enhance the benefits of existing vaccines and prophylactics, it said.On Stocktwits, retail sentiment around Cidara soared from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_1_07_39_PM_png_569e678349.webp" alt="CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits" width="627" height="67"><figcaption>CDTX's Sentiment Meter and Message Volume as of 1:05 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user highlighted the company’s debt-free status and strong cash position.<stembedurl>https://stocktwits.com/Vulcooo/message/618688709</stembedurl>Cidara ended the first quarter with $174.5 million in cash, cash equivalents, and restricted cash.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up by about 56% this year and by about 272% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/compass-pathways-stock-slumps-after-positive-late-stage-trial-results-from-psychedelic-drug-underwhelm-analysts/chm59LwRRdc">Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Cidara Therapeutics’ Market Cap Doubles After Investigational Drug Shows Positive Results In Preventing Influenza In Mid-stage Trial

Single doses of 450mg, 300mg, and 150mg of CD388 conferred 76%, 61%, and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo, the company said.

Cidara Therapeutics: A Strong Buy on Promising Trials and Strategic Milestones

Cidara Therapeutics (CDTX Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer...

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX

CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX CDTX INVESTOR NOTICE: ROSEN, TOP...

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CDTX News

CDTXCidara Therapeutics Inc